Dr. Nicolaides has been on our board of directors since joining in April of 2015. He is the president and co-founder of Morphotek, a biopharmaceutical company specializing in the development of protein and antibody products for treating cancer, inflammation and infectious disease. Dr. Nicolaides’ post-graduate research at Johns Hopkins Medical School was the basis for the company’s inception. In the spring of 2007, Morphotek was acquired by Eisai Co. Ltd, a global health care pharmaceutical company. Prior to co-founding Morphotek, Dr. Nicolaides was the director of research at Magainin Pharmaceuticals, where his research focused on the development of bio-therapeutics to treat respiratory disease. He is a trained molecular geneticist and has authored a number of scientific papers on the molecular and genetic basis of cancer and respiratory diseases. He received his B.S. in biology at St. Joseph’s University, his Ph.D. in human genetics at Thomas Jefferson University and continued his training as a Fellow in Oncology at Johns Hopkins University. Dr. Nicolaides is an author on more than 50 original publications and is an inventor on numerous patents for developing bio-based therapies and therapeutic compositions.

 Bio-therapeutics